COPD, page-13

Sorry, I'm not having a dig. We all know biotech stocks are high risk, high reward. I don't think Invion is a basket case. Far from it. That's why I'm still keeping an eye on the stock and won't rule out buying back in. I'm not annoyed at the company. Ultimately, investing comes with risks and you live with the consequences. I am annoyed though with the manner Australian Small Cap Investigator handled this stock - a change in editor should not result in a 360 degree turnaround in sentiment from a ranging buy to a sell in a matter of weeks. I've said as much before. My comment about my doctor relatives was said tongue in cheek, so don't take it personally. Anyway, let's all hope July brings great results. p.s. doctors know lots more about drug development, etc than you think. I bought Sirtex on the recommendation of my haematologist brother in law when the stock was off the radar.